Results 91 to 100 of about 159,270 (192)

Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab

Pediatric Dermatology, EarlyView.
ABSTRACT Bowel‐associated dermatosis‐arthritis syndrome (BADAS) is a rare neutrophilic dermatosis characterized by recurrent fever, arthralgias, and skin eruptions, most commonly occurring in patients with inflammatory bowel disease. We report the case of a 17‐year‐old female with Crohn's disease who developed BADAS and achieved complete and durable ...
Kylie E. Peake, Harman Toor, Marie‐Christine Jean, Collin C. Barker, Joseph M. Lam   +4 more
wiley   +1 more source

Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases

Mediators of Inflammation, 2019
Monogenic autoinflammatory diseases (mAIDs) are inherited errors of innate immunity characterized by systemic inflammation recurring with variable frequency and involving the skin, serosal membranes, synovial membranes, joints, the gastrointestinal tube,
Carla Gaggiano, Donato Rigante, Antonio Vitale, Orso Maria Lucherini, Alessandra Fabbiani, Giovanna Capozio, Chiara Marzo, Viviana Gelardi, Salvatore Grosso, Bruno Frediani, Alessandra Renieri, Luca Cantarini   +11 more
doaj   +1 more source

Of mice and men—The emerging oral–gut–brain axis of health and disease

Periodontology 2000, EarlyView.
Abstract Objectives Oral health's inextricable links to systemic health are highlighted by the emerging oral–gut–brain axis and other well‐known axes. There is growing evidence of a complex oral–gut–brain axis linking mouth and gut microbiomes with the central nervous system.
Yvonne L. Hernandez‐Kapila, Daniel J. Weisenberger   +1 more
wiley   +1 more source

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

American Journal of Hematology, Volume 101, Issue 9, Page 2166-2176, September 2026.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima, Margaret Mei‐Kay Wong, Jesus Gonzalez‐Lugo, Susan M. Geyer, Ali Alsugair, Maria Sirenko, Kimberly J. Langer, Terra L. Lasho, Christy Finke, Jun Choi, Maher Abdul‐Hay, Gary Ho, Mark R. Litzow, Aasiya Matin, Urshila Durani, Mehrdad Hefazi, William J. Hogan, Mithun V. Shah, Aref Al‐Kali, Kebede H. Begna, Naseema Gangat, Antoine N. Saliba, Ronald S. Go, Tariq Kewan, Gabriel Bartoo, Jade Kutzke, Kristen McCullough, Kenneth J. Warrington, Megan Sullivan, Kaaren K. Reichard, Horatiu Olteanu, Hemant Murthy, Talha Badar, Yael Kusne, Jeanne Palmer, Saurabh Chhabra, Nathan Punwani, Mary Riwes, Joseph P. McGuirk, Elizabeth F. Krakow, Amelia Langston, Taxiarchis Kourelis, David Dingli, James Foran, Matthew J. Koster, Mrinal M. Patnaik, David B. Beck, Hassan B. Alkhateeb, Abhishek A. Mangaonkar   +48 more
wiley   +1 more source

The IL‐10/IL‐6 Ratio and the Risk Score: Two Cytokines‐Based Predictors for Malignancy‐Associated Hemophagocytic Lymphohistiocytosis in Adults (M‐HLHa)

American Journal of Hematology, Volume 101, Issue 9, Page 2214-2224, September 2026.
ABSTRACT The predictive value of cytokines (CK) for malignancy‐associated adult hemophagocytic lymphohistiocytosis (M‐HLHa) remains uncertain. We evaluated a cytokine‐based Risk Score (RS) and the IL‐10/IL‐6 Ratio to predict M‐HLHa. Adult patients (n = 112) from the French HLH cohort (NCT02113917) with complete data for nine key HLH related CK measured
Coralie Bloch, Stephanie Chhun, Nanthara Sritharan, Marine Gil, Raphael Lhote, Marouane Boubaya, Olivier Lambotte, David Launay, Claire Larroche, Estibaliz Lazaro, Francois Liffermann, Marc Michel, Jean‐Marie Michot, Pierre Morel, Louis Terriou, Geoffrey Urbansk, Jean‐Francois Viallard, Morgane Cheminant, Felipe Suarez, Yves Lepelletier, Geneviève de Saint Basile, Olivier Hermine, the French HLH Study Group, Coralie Bloch, Jean Philippe Jais, Francois Liffermann, Pierre Morel, Morgane Cheminant, Felipe Suarez, Olivier Hermine, Fabrice Bonnet, Pascal Godemer, Damaj Gandhi, Olivier Fain, Olivier Lambotte, David Launay, Louis Terriou, Claire Larroche, Estibaliz Lazaro, Jean‐Francois Viallard, Francois Liffermann, Olivier Lortholary, Marc Michel, Jean‐Marie Michot, Pierre Morel, Frederic Pene, Antoinette Perlat, Geoffrey Urbanski   +47 more
wiley   +1 more source

Diagnosis, management, and monitoring of interleukin-1 mediated diseases in Central and Eastern Europe: real-world data

Pediatric Rheumatology Online Journal
Background Global healthcare disparities, stemming from organizational differences in healthcare systems, lead to variable availability and funding, resulting in a gap between recommended and implemented practices for interleukin (IL)-1-mediated ...
Marija Jelusic, Mario Sestan, Natasa Toplak, Constantin Tamas, Jelena Vojinovic, Zbigniew Zuber, Beata Wolska-Kusnierz, Mihaela Sparchez, Milos Jesenak, Skirmante Rusoniene, Valda Stanevica, Pavla Dolezalova, Liora Harel, Yosef Uziel, Marco Gattorno   +14 more
doaj   +1 more source

Is Still's Disease an Autoinflammatory Syndrome?

International Journal of Inflammation, 2012
Systemic juvenile idiopathic arthritis (sJIA), formerly called Still's disease, is officially classified as a subset of juvenile idiopathic arthritis (JIA).
Linda Rossi-Semerano, Isabelle Koné-Paut   +1 more
doaj   +1 more source

Report on the 13th international workshop on the CCN family of genes and inaugural ARBIOCOM conference, Nice, France

Journal of Cell Communication and Signaling, Volume 20, Issue 3, September 2026.
Celebration of the 13th ICCNS meeting joint to the 1st ARBIOCOM Conference held on the site of Nice in December 2025. Abstract The 13th International Workshop on the CCN Family of Genes, held in Nice as part of the inaugural ARBIOCOM World Conference, brought together investigators with diverse research backgrounds, disciplines, and expertise. Building
Bernard Perbal, Ralf Weiskirchen, Annick Perbal, Brahim Chaqour   +3 more
wiley   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 753-761, September 2026.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu, Ji Eun Ryoo, Brian S. Henick, Adam Mor   +3 more
wiley   +1 more source